The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma (DRBEAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01235793
Recruitment Status : Recruiting
First Posted : November 8, 2010
Last Update Posted : January 16, 2018
Information provided by (Responsible Party):
Yuliya Linhares, Cedars-Sinai Medical Center

Brief Summary:

The primary purpose of the study will be testing the dosing of temozolomide to find the target dose that a person can tolerate. The other part of the study will be determining how helpful it can be to CNS lymphoma patients by adding temozolomide to the "conditioning regimen" prior to stem cell transplantation.

This research study is designed to test the investigational use of temozolomide as part of a conditioning regimen prior to stem cell transplantation. This drug has not yet been approved by the U.S. Food and Drug Administration (FDA) to be used in the setting of stem cell transplantation in lymphomas of the brain (central nervous system or CNS) but it has been studied and used before in transplantation with reasonable results.

Condition or disease Intervention/treatment Phase
B-Cell Lymphoma Originating in the CNS Drug: Temozolomide Phase 2

Detailed Description:

Currently there is no standard of care for relapsed or refractory primary central nervous system (CNS) lymphoma. After high-dose methotrexate or radiation therapy, the best approach to relapsed disease is undefined. Common practice is the regimen RBEAM as a conditioning regimen in this patient population prior to transplantation. The RBEAM regimen includes R (rituximab), B (BCNU), E (etoposide), A (Ara-C (cytarabine)) and M (melphalan). In addition, dexamethasone is included in the regimen although not noted in the RBEAM mnemonic. However, the melphalan used in this combination is not thought to have much CNS penetration. Therefore, temozolomide, an alkylating agent known to penetrate the CNS and approved by the FDA for brain tumors will be used and evaluated in this study instead of melphalan.

The aim of this study is to determine an effective and safe dose of temozolomide orally administered to patients with relapsed primary CNS lymphoma over the 5 days preceding autologous stem-cell transplantation. The hope is that the conditioning regimen DRBEAT [D (dexamethasone) (R (rituximab), B (BCNU), E (etoposide), A (Ara-C (cytarabine)) and T (temozolomide)] will significantly improve the survival of patients with relapsed CNS lymphoma.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma
Actual Study Start Date : October 14, 2010
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: DRBEAT Regimen Drug: Temozolomide
The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.

Primary Outcome Measures :
  1. Efficacy of the DRBEAT Regimen [ Time Frame: One Year ]

    Efficacy of the DRBEAT Regimen will be assessed by analysis of

    1. one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression, or death,


    2. Overall survival, defined as the time interval between the date of transplant and the date of death from any cause.

  2. Safest dose of temozolomide for the DRBEAT Regimen [ Time Frame: One year ]
    Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients ≥ 18 years of age and ≤ 75 years of age
  2. Patients must have Central Nervous System (CNS) involvement with a mature B-cell non-Hodgkin's Lymphoma, (WHO criteria)
  3. Patients must meet one of the below criteria:

    • Patients who have achieved a complete response (CR) or partial response (PR) after initial therapy for Central Nervous System (CNS) B-cell lymphoma, OR
    • Patients with relapsed or progressed disease following therapy for CNS B-cell lymphoma who has achieved a subsequent CR or PR following salvage chemotherapy, OR
    • Patients who are initially refractory to therapy for CNS B-cell lymphoma but who have achieved a CR or PR following a salvage chemotherapy regimen, OR
    • Patients who have developed CNS relapse from systemic B-cell Non-Hodgkin's lymphoma, and have evidence of chemotherapy sensitive lymphoma.
  4. Patients fit for autologous stem cell transplantation
  5. Patients able to understand and willing to sign a written informed consent document

Exclusion Criteria:

  1. Patients whose life expectancy is severely limited by diseases other than malignancy
  2. Karnofsky Performance Score <60
  3. Patients who are pregnant or breastfeeding
  4. Patients who are HIV seropositive
  5. Patients who have an uncontrolled infection (presumed or documented) with progression after appropriate therapy for greater than one month
  6. Patients with symptomatic coronary artery disease, uncontrolled congestive heart failure. Left Ventricular Ejection Fraction is not required to be measured, however if it is measured, patient is excluded if ejection fraction is <30%
  7. Patients requiring supplementary continuous oxygen. DLCO is not required to be measured, however if it is measured, patient is excluded if DLCO <35%.
  8. Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function and histology, and for the degree of portal hypertension. Patients with any of the following liver function abnormalities will be excluded

    1. Fulminant liver failure
    2. Cirrhosis with evidence of portal hypertension or bridging fibrosis
    3. Alcoholic hepatitis
    4. Esophageal varices
    5. A history of bleeding esophageal varices
    6. Hepatic encephalopathy
    7. Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time
    8. Ascites related to portal hypertension
    9. Chronic viral hepatitis with total serum bilirubin >3 mg/dL
    10. Symptomatic biliary disease
  9. Patients with non-B-cell lymphomas or brain tumors that are not lymphomas are Excluded from the study. Non-B-cell lymphomas include: any T-cell lymphoma, natural killer (NK)-cell lymphomas, and Hodgkin lymphomas
  10. Patients for whom an insufficient number of stem cells (<2 X 106/kg) have been collected

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01235793

Contact: Tu Nguyen 310-423-0192

United States, California
Cedars Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Hannah Coleman    310-967-4376   
Sub-Investigator: Jethro Hu, MD         
Sub-Investigator: Yuliya Linhares, MD         
Sub-Investigator: Jeremy Rudnick, MD         
Principal Investigator: Michael Lill, MD         
Sub-Investigator: Noah Merin, MD         
Sponsors and Collaborators
Cedars-Sinai Medical Center
Principal Investigator: Michael Lill, MD Cedars-Sinai Medical Center
Principal Investigator: Yuliya Linhares, MD Cedars-Sinai Medical Center

Additional Information:
Jeffrey Raizer, DeAngelis Lisa, Andrew Zelenetz et al. Activity of Rituximab in Primary Central Nervous System Lymphoma PCNSL. Proc Am Soc Clin Oncol 19: 2000 (abstr 642)
Agarwala SS, Reyderman L, Statkevich P et al Pharmacokinetic phase I study of temozolomide penetration into CSF in a patient with dural melanoma. Annals of Oncology, supplement 4 to volume 9, 1998, abstract 659 page 138
Skeel R. Antioneoplastic Drugs and Biologic Response Modifiers: Classification, Use, and Toxicity of Clinically Useful Agents. Pp64-66 in Handbook of Cancer Chemotherapy, 5th edition 1999, Editor Skeel R
Chabner B. Adduct-Forming Agents: Alkylating Agents and Platinum Analogs. Pp 52-53 in Harrison's Manual of Oncology 2008. Editors Chabner BA, Lynch TJ, Longo DL
Issa S, Hwang J, Karch J, et al. Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 7595
Handbook of statistics in clinical oncology By John Crowley, Donna Pauler Ankerst Pahse 1 Trials Page 8 Edition 2, 2005
Lowsky et al. Research Protocol for California AML Study.
Zacks s, Rogatko A, Babb J. Optimal Bayesian-feasible dose escalation for cancer phase I trials. Statistics & Probability Letters, 1998, vol. 38, issue 3, pages 215-220
Xu Z, Tighiouart M, Rogatko A. 2007 EWOC 2.0: Interactive Software for Dose Escalation in Cancer Phase I Clinical Trials, Drug Information Journal, 41(2):221-228

Responsible Party: Yuliya Linhares, Interim Lead Investigator, Staff Physician, Cedars-Sinai Medical Center Identifier: NCT01235793     History of Changes
Other Study ID Numbers: Pro00019873
First Posted: November 8, 2010    Key Record Dates
Last Update Posted: January 16, 2018
Last Verified: January 2018

Keywords provided by Yuliya Linhares, Cedars-Sinai Medical Center:
Primary Central Nervous System B-cell Lymphoma
Autologous Stem Cell Transplant
B-Cell Lymphoma
Conditioning Regimen

Additional relevant MeSH terms:
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents